Neuroleptic-Associated Hyperprolactinemia: Clinical Manifestations and Effects on Sexual Function

Yunilainen, O. A.; Старостина, Е. Г.; Dzeranova, Larisa; Kudryashkina, G N; Kesselman, L G; Баранов, П. А.; Дедов, И И

doi:10.1007/s11055-018-0571-y

Cited by 2 publications

(11 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Half of the clinical trials (10/20; 50%) applied a randomised parallel design, while nearly one-third of observational studies (9/30; 30%) were case series or case reports. Over half of the clinical trials were conducted in Asia (55%; 11/20) [ 15 – 25 ], while most observational studies took place in European (43%; 13/30) or Asian countries (37%; 11/30) [ 26 – 38 ]. Study settings at the time of patient enrolment were not reported in 36% (18/50) of the included studies.…”

Section: Summary Of Findingsmentioning

confidence: 99%

“…One clinical trial was conducted from 1987 to 1991 (totalling 4 years of enrolment) [ 16 ]. Among the observational studies that reported the enrolment period, 71% (12/17) enrolled patients from 2000 to 2018 [ 10 , 28 , 34 , 38 , 43 , 46 , 47 , 49 , 52 – 55 ]. The remaining studies (5/17; 29%) were conducted between 1976 and 1988 [ 27 , 35 , 36 , 48 , 50 ].…”

Section: Summary Of Findingsmentioning

confidence: 99%

“…Sixteen clinical trials (of 20; 80%) [ 15 – 22 , 25 , 41 , 42 , 50 , 56 , 57 , 60 , 61 ] and 21 observational studies (of 30; 70%) reported data on breast and lactation disorders in people with drug-induced HPL [ 10 , 26 – 28 , 30 , 31 , 33 – 36 , 38 , 43 , 46 , 47 , 49 , 50 , 52 – 54 , 58 , 59 ]. Among the clinical trials, galactorrhoea was the most frequently observed presentation of HPL, occurring in 4–62% of patients.…”

Section: Summary Of Findingsmentioning

confidence: 99%

“…The higher frequencies of 34% and 60% were described in patients treated with antipsychotics [ 28 , 36 ], and a prevalence of 29% was reported among patients receiving antidepressants. One study described gynaecomastia in 25% (10/40) of males with HPL induced by antipsychotics [ 38 ], and one study reported breast pain occurring in 12% of patients exposed to antidepressants [ 36 ].…”

Section: Summary Of Findingsmentioning

confidence: 99%

“…One observational study (of 30; 3%) [ 38 ] reported data on female patients with drug-induced HPL presenting with genital system disorders. The symptom related to vaginal dryness during intercourse, assessed by the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ) scale, was reported in up to 53% (42/80) of females treated with antipsychotics [ 38 ]. Table S7 provides further details on clinical presentations of female genital system disorders.…”

Section: Summary Of Findingsmentioning

confidence: 99%

See 4 more Smart Citations

Clinical Presentations of Drug-Induced Hyperprolactinaemia: A Literature Review

et al. 2023

View full text Add to dashboard Cite

Screening for drug-induced hyperprolactinaemia, a condition characterised by higher-than-normal levels of serum prolactin induced by drug treatments, requires a comprehensive understanding of the clinical presentations and long-term complications of the condition. Using two databases, Embase and MEDLINE, we summarised the available evidence on the clinical presentations and long-term complications of drug-induced hyperprolactinaemia. Clinical and observational studies reporting on drug treatments known or suspected to induce hyperprolactinaemia were included. Database searches were limited to the English language; no date or geographic restrictions were applied. Fifty studies were identified for inclusion, comprising a variety of study designs and patient populations. Most data were reported in patients treated with antipsychotics, but symptoms were also described among patients receiving other drugs, such as prokinetic drugs and antidepressants. Notably, the diagnosis of drug-induced hyperprolactinaemia varied across studies since a standard definition of elevated prolactin levels was not consistently applied. Frequent clinical presentations of hyperprolactinaemia were menstrual cycle bleeding, breast or lactation disorders, and sexual dysfunctions, described in 80% (40/50), 74% (37/50), and 42% (21/50) of the included studies, respectively. In the few studies reporting such symptoms, the prevalence of vaginal dryness impacted up to 53% of females, and infertility in both sexes ranged from 15 to 31%. Clinicians should be aware of these symptoms related to drug-induced hyperprolactinaemia when treating patients with drugs that can alter prolactin levels. Future research should explore the long-term complications of drug-induced hyperprolactinaemia and apply accepted thresholds of elevated prolactin levels (i.e., 20 ng/mL for males and 25 ng/mL for females) to diagnose hyperprolactinaemia as a drug-induced adverse event. Trial Registration PROSPERO International Prospective Register Of Systematic Reviews (CRD42021245259). Supplementary Information The online version contains supplementary material available at 10.1007/s40290-023-00462-2.

show abstract

Section: Summary Of Findingsmentioning

confidence: 99%